Eagle Pharmaceuticals Stock News

Eagle Pharmaceuticals (EGRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Equities research analysts expect that Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) will post earnings per share of $0.89 for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Eagle Pharmaceuticals earnings, with the lowest EPS estimate coming in at $0.86 and the highest estimate coming in at $0.92. Eagle Pharmaceuticals reported earnings of $0.96 []

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Eagle Pharmaceuticals Inc said on Wednesday the U.S. health regulator approved its generic version of Endo Internationals blood pressure drug, Vasostrict, sending its shares to a more than one-month high. The U.S. Food and Drug Administrations approval comes just months after a Delaware federal court ruled that Eagles proposed generic, vasopressin, did not infringe on []

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron Variant Vir Biotechnology, Inc.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) shot up 4.1% during mid-day trading on Monday . The company traded as high as $47.71 and last traded at $47.71. 236 shares were traded during trading, a decline of 100% from the average session volume of 108,067 shares. The stock had previously closed at $45.82. A number of brokerages have []

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple conference presentations

Bank of America Corp DE cut its holdings in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 7.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 60,443 shares of the specialty pharmaceutical companys stock after selling 5,069 shares during the quarter. Bank of America []

Wells Fargo & Company MN boosted its position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 226.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 173,765 shares of the specialty pharmaceutical companys stock after buying an additional 120,473 shares during the quarter. Wells Fargo []

Zacks Investment Research upgraded shares of Eagle Pharmaceuticals (NASDAQ:EGRX) from a hold rating to a buy rating in a research note issued to investors on Friday morning, Zacks.com reports. They currently have $54.00 target price on the specialty pharmaceutical companys stock. According to Zacks, Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on []

Eagle Pharmaceuticals (NASDAQ:EGRX) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Friday, Zacks.com reports. The firm presently has a $54.00 price target on the specialty pharmaceutical companys stock. Zacks Investment Researchs price target would suggest a potential upside of 13.88% from the []

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date peri

POINT Biopharma Global (NASDAQ:PNT) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends. Insider & Institutional Ownership 39.9% of POINT Biopharma Global shares are held by institutional []